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Background: The effect of norepinephrine in patients with septic shock remains controversial. We conducted a
meta-analysis to compare the mortality rates and benefits of norepinephrine and vasopressin.
Methods: PubMed, EMBASE, and the Cochrane Library database were searched from database inception to
December 2013. We selected randomized controlled trials in adults with septic shock and compared norepinephrine
with vasopressin. After assessing the heterogeneity of treatment effects across trials using the I2 statistic, we used a
fixed effects model (P ≥ 0.1) and expressed the results as risk ratios (RRs) for dichotomous outcomes or as standardized
mean differences (SMDs) for continuous data with 95% confidence intervals (CIs). Meta-analysis was conducted using
Review Manager 5.1 software.
Results: Seven trials (n = 2323) met the inclusion criteria. Overall, the mortality rate in these seven trials was 36.2%
(840/2323). There was no difference in mortality following the use of norepinephrine or vasopressin (RR 1.07; 95%CI
0.97-1.20; P = 0.19). Compared to norepinephrine, vasopressin had no significant effect on heart rate (HR) (SMD
0.21; 95%CI −0.08-0.50; P = 0.15), mean arterial pressure (MAP) (SMD 0.15; 95%CI −0.15-0.44; P = 0.33), cardiac index
(CI) (SMD −0.10; 95%CI −0.64-0.44; P = 0.73), systemic vascular resistance index (SVRI) (SMD 0.15; 95%CI −0.39-0.70;
P = 0.58), oxygen delivery (DO2) (SMD −0.06; 95%CI −0.62-0.49; P = 0.82), oxygen consumption (VO2) (SMD 0.03;
95%CI −0.52-0.59; P = 0.91) or lactic acid (SMD 0.07; 95%CI −0.23-0.36; P = 0.66). No significant heterogeneity was
found in these comparisons (P ≥ 0.1).
Conclusions: There is not sufficient evidence to prove conclusively that norepinephrine is superior to vasopressin
in terms of mortality and hemodynamics. The effects of norepinephrine and vasopressin on patients with septic
shock require further study in large randomized controlled trials.
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Septic shock is one of the most challenging medical
problems, and severe sepsis accounts for 20% of all
admissions to intensive care units (ICUs), including
750,000 cases annually in the United States, with a
mortality rate ranging from 28% to 50% [1,2]. The initial
goal-directed resuscitation for septic shock typically
includes the administration of intravenous fluids and
vasopressors. Although norepinephrine is commonly
used and is the recommended agent for the treatment* Correspondence: zhoufh301@126.com
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article, unless otherwise stated.of hypotension in volume-resuscitated hyperdynamic
septic shock [3], the effect of norepinephrine on patient-
relevant outcomes remains controversial. Recent evidence
from a large-scale study revealed that there was no signifi-
cant difference in the mortality rate between patients
with septic shock who were treated with dopamine as
the first-line vasopressor agent and those who were
treated with norepinephrine [4].
Vasopressin is an endogenously released hormone that
has recently emerged as an adjunct to catecholamines
for patients with septic shock requiring vasopressor sup-
port [5]. When compared with norepinephrine, a study
has shown that vasopressin treatment in septic shock istral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Quorum chart of the study cohort. The search was conducted using the PubMed, EMBASE, and Cochrane Library databases from
database inception to December 2013.
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change in cardiac output or other measures of perfusion
[6]. Daley et al. revealed that vasopressin was not inferior
to norepinephrine for the achievement of a mean arterial
pressure (MAP) goal within the first 6 hours following
the onset of septic shock [7]. In another study, Russell
et al. demonstrated that low-dose vasopressin did not
reduce mortality rates when compared with norepineph-
rine among patients with septic shock who were treated
with catecholamine vasopressors [8].
Due to the continuing controversy regarding whether
norepinephrine is superior to vasopressin, we performed
a meta-analysis to attempt to determine whether norepin-
ephrine is more effective than vasopressin in reducing
overall mortality and improving hemodynamics in septic
shock.Table 1 Characteristics of the included trials
Source Number of patients Mean age (years) Male (%
Russell JA, 2013 [12] 394 62.8 233 (59.1
Daley MJ, 2013 [7] 130 58.5 69 (53.1)
Gordon AC, 2010 [13] 778 61.8 475 (61.0
Russell JA, 2009 [14] 190 61 116 (61.1
Morelli A, 2009 [15] 45 65.7 33 (73.3)
Russell JA, 2008 [8] 778 60.6 475 (61.1
Lauzier F, 2006 [16] 23 54.7 14 (60.9)
APACHE, acute physiology and chronic health evaluation; SAPS, simplified acute ph
pressure; S, single-center trial; M, multicenter trial; NE, norepinephrine; NR, not repoMethods
We performed this meta-analysis following the recom-
mendations of the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA statement)
guidelines [9].Eligibility criteria and information sources
We searched for literature in the PubMed (US National
Library of Medicine, Bethesda, MD, USA), EMBASE and
Cochrane Library databases from database inception to
December 2013. The article types were primarily limited
to randomized controlled trials (RCTs) that included
patients aged older than 18 years. We also scanned the
bibliographies of all relevant studies and recent review
articles to identify additional citations.) Center Mean APACHE II/
SAPS II/SOFA score
Blood pressure (mmHg)
) M 26.8/NR/NR MAP <65
S 27.8/NR/NR MAP <65
) M 27.1/NR/NR MAP 72.7 (NE maintenance)
) M 26.5/NR/NR MAP <60
S NR/60/NR MAP <65
) M 27.1/NR/NR MAP 72.5 (vasopressor maintenance)
M 23.2/NR/8.9 MAP <60
ysiology score; SOFA, sequential organ failure assessment; MAP, mean arterial
rted.
Table 2 Quality assessment of the six randomized controlled trials included in the meta-analysis
Source Randomization Allocation concealment Blinding Description of withdrawals and dropouts Jadad score
Russell JA, 2013 [12] Yes Uncertain Yes Yes 3
Gordon AC, 2010 [13] Yes Adequate Yes Yes 5
Russell JA, 2009 [14] Yes Adequate Yes Yes 5
Morelli A, 2009 [15] Yes Adequate Uncertain Yes 3
Russell JA, 2008 [8] Yes Adequate Yes Yes 5
Lauzier F, 2006 [16] Yes Adequate Uncertain Yes 3
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We used medical subject heading (MeSH) terms and
text words with a Boolean strategy. Cross-searching was
performed based on the following 2 categories: (1) differ-
ent vasopressors (“norepinephrine” OR “vasopressin”); (2)
disease (“sepsis” OR “infection” OR “septic shock” OR
“shock” OR “systemic inflammatory response syndrome”
OR “SIRS”). The limits placed on the literature searches
were “human” and “English”.Study selection
The study selection was performed by two independ-
ent investigators (F.Z. and Q.S.). Studies that compared
mortality between norepinephrine and vasopressin use in
patients (aged ≥18 years) with septic shock were evaluated
and included.Data extraction
Raw data were extracted using a standard form for each
study, which included the study design, year of publica-
tion, total number of patients, and patient characteristics.
The main endpoint was 28-day mortality. If mortality was
assessed at several time points or only at an undetermined
time point in a study, we used data from the last follow-
up or the only undetermined time point.Figure 2 Risk ratio of mortality for norepinephrine versus vasopressin
CI indicates the confidence interval; The size of the data markers indicatesQuality assessment
The quality of each study included in the meta-analysis was
assessed using the Jadad score [10], including the proper
conduct of randomization, concealment of treatment allo-
cation, similarity of treatment groups at baseline, clinician
blinding, and the description of withdrawals and dropouts.Statistical analysis
Statistical analyses were performed using Review Manager,
version 5.1 (RevMan, The Cochrane Collaboration, Oxford,
the United Kingdom). After assessing for the heterogeneity
of treatment effects across trials using the I2 statistic [11],
we used a fixed effects model (P ≥ 0.1). The results were
expressed as risk ratios (RRs) for dichotomous outcomes
or standardized mean differences (SMDs) for continuous
data with 95% confidence intervals (CIs), and P < 0.05 was
considered significant. Publication bias was assessed using
funnel plots.Results
Study selection
A total of 1995 studies were identified. We retrieved 35
articles for detailed evaluation, of which 28 were excluded
(Figure 1). Seven trials (2323 patients) met the criteria
for inclusion [7,8,12-16]. All studies compared the effects
of norepinephrine and vasopressin in patients with. Pooled risk ratios (RRs) were obtained using a fixed effects model;
the weight of the study.
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hemodynamics, or acute physiology and chronic health
evaluation (APACHE) II score (Table 1).
Study characteristics
Five multicenter studies [8,12-14,16] and two single-center
studies [7,15] were identified. The characteristics of the
included trials are shown in Table 1. These trials wereFigure 3 Effect of norepinephrine versus vasopressin on hemodynam
pressure; CI, cardiac index; SVRI, systemic vascular resistance index; DO2, ox
arterial pressure; SMD, standardized mean difference; CI, confidence intervareported between 2006 and 2013, and the mean age
of the study participants ranged between 54.7 and
62.8 years. The proportion of men ranged from 53.1%
to 61.1%. The mean APACHE II score was between
23.2 and 27.8. All patients with sepsis or septic shock
were diagnosed according to the American College of
Chest Physicians/Society of Critical Care Medicine
Consensus Conference criteria [17].ic and metabolic parameters. HR, heart rate; MAP, mean arterial
ygen delivery; VO2, oxygen consumption; MPAP, mean pulmonary
l; IV, inverse variance method.
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Six of the citations included [8,12-16] were randomized
controlled trials, and one was a cohort study [7]. Blind-
ing was performed in four studies [8,12-14]. The mean
Jadad score of the six randomized controlled trials was 4
(Table 2).Effect of norepinephrine versus vasopressin on mortality
The mortality rate in the seven trials was 36.2% (840/
2323). No difference in mortality was identified when
comparing norepinephrine and vasopressin (RR 1.07;
95%CI 0.97-1.20; P = 0.19). No significant heterogeneity
was found in this comparison (I2 = 0%, P = 0.51) and the
fixed effects model was used (Figure 2). Because one
trial [7] was a cohort study, we also performed a meta-
analysis of the other six trials [8,12-16]. Similarly, no
difference in mortality was found when comparing
these two groups (RR 1.07; 95%CI 0.96-1.20; P = 0.22;
I2 = 5%, P = 0.39).Effect of norepinephrine versus vasopressin on
hemodynamic and metabolic parameters
Compared to norepinephrine, vasopressin had no signifi-
cant effect on heart rate (HR) (SMD 0.21; 95%CI −0.08-
0.50; P = 0.15), MAP (SMD 0.15; 95%CI −0.15-0.44;
P = 0.33), cardiac index (CI) (SMD −0.10; 95%CI −0.64-
0.44; P = 0.73), systemic vascular resistance index (SVRI)
(SMD 0.15; 95%CI −0.39-0.70; P = 0.58), oxygen deliv-
ery (DO2) (SMD −0.06; 95%CI −0.62-0.49; P = 0.82),
oxygen consumption (VO2) (SMD 0.03; 95%CI −0.52-0.59;
P = 0.91) or lactic acid (SMD, 0.07; 95%CI −0.23-0.36;
P = 0.66). No significant heterogeneity was found in these
comparisons (P ≥ 0.1, Figure 3).Figure 4 Assessment of publication bias using a funnel plot.Publication bias analyses
Publication bias was evaluated using a funnel plot, and
the primary comparisons of mortality are presented. The
funnel plots of this primary outcome did not suggest
major asymmetry, indicating no significant publication
bias (Figure 4).
Discussion
Seven trials including 2323 patients with septic shock
that compared the use of norepinephrine to vasopressin
were identified and included in this review. The main
results revealed that the survival of patients treated with
norepinephrine was not significantly different from those
treated with vasopressin. Furthermore, there was also no
evidence indicating that norepinephrine is superior to
vasopressin in improving hemodynamics.
Vasopressors should be initiated in patients with septic
shock if fluid resuscitation fails to restore adequate arterial
pressure and organ perfusion, and the effects of vasopres-
sors differ based on the targeted adrenergic receptors,
resulting in heterogeneity of their physiological effects
[18]. Although both dopamine and norepinephrine are
recommended as first-line vasopressor agents in the
treatment of septic shock [3], vasopressin, which is a
peptide hormone released by the pituitary in response
to decreased intravascular volume, has been used in
patients with septic shock [18,19]. In a multi-center
double-blind randomized controlled trial of vasopressin
versus norepinephrine in adult patients who had septic
shock, Gordon et al. revealed that patients with septic
shock who were at risk of kidney injury had reduced
progression to renal failure and reduced 28-day mortality
when treated with vasopressin in comparison to those
treated with norepinephrine [13]. However, our meta-
analysis did not find a significant difference in mortality
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consistent with more recent randomized clinical trials
[8,15,16]. It is likely that no single pressor has been defini-
tively shown to have a mortality benefit over another in
patients with septic shock. It is possible that a continuous
infusion of low-dose vasopressin, when given as first-line
vasopressor agent in septic shock, is effective in reversing
sepsis-induced arterial hypotension and reducing norepin-
ephrine requirements.
For septic patients, once the inflammatory response
has been induced, a marked decrease in the SVRI results
from arterial and venous dilation, which is accompanied
by leakage of plasma into the extravascular space, leading
to relative hypovolemia [20]. Recent randomized clinical
trials demonstrated that survivors of septic shock had
greater decreases in cytokines, chemokines and growth
factors in early septic shock. Furthermore, vasopressin
decreased 24-hour plasma cytokine levels more than did
norepinephrine [12]. In the present study, we compared
norepinephrine to vasopressin and found no significant
differences in HR, MAP, CI, or SVRI. This was not con-
sistent with a previous trial [16], in which vasopressin was
reported to increase the SVRI and decrease the CI when
compared with baseline, whereas norepinephrine did
not [16]. The hemodynamic impact of norepinephrine
on the treatment of septic shock compared to vasopres-
sin, however, requires further evaluation in randomized
clinical trials.
For patients with septic shock, it is imperative to restore
adequate perfusion pressure and oxygen delivery. It is
evident that inadequate systemic hemodynamics, i.e.,
systemic DO2 and VO2, can impair splanchnic blood flow
and oxygenation [21]. Although increased renal circulation
and splanchnic blood flow have been reported in cases of
hyperdynamic septic shock treated with norepinephrine
[22-24], no significant differences in DO2, VO2 or lactate
were found between norepinephrine and vasopressin
in our meta-analysis. Because one of the rationales for
catecholamine administration in septic patients is to
increase DO2 due to the relationship between DO2 and
VO2 [25], norepinephrine may therefore be questionable
as a preferential treatment when compared with vasopres-
sin in this context.
There are some limitations to this meta-analysis. First,
although the mean Jadad score of the included trials was
4, indicating that most of the trials were of high quality,
one cohort study was included in this meta-analysis,
which may limit the strength of the analysis. Second,
although seven trials were included in the analysis, the
actual sample size for specific comparisons in sub-
group analyses was small, and publication bias was
only evaluated using a funnel plot with seven studies,
which may have affected the findings. The effects of
norepinephrine and vasopressin in patients with septicshock require further evaluation in large-scale randomized
controlled trials.
Conclusions
In conclusion, pooled results of seven trials show that
there is not sufficient evidence to prove conclusively that
norepinephrine is superior to vasopressin in terms of mor-
tality and hemodynamics. The effects of norepinephrine
and vasopressin on patients with septic shock require
further study in large randomized controlled trials.
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